Features Partner Sites Information LinkXpress
Sign In
Demo Company

New Agent Found to Suppress Cognitive Impairment of Alzheimer’s Disease

By BiotechDaily International staff writers
Posted on 25 Nov 2013
Print article
A unique new compound has been shown to prevent cognitive impairment and oxidative stress in animal lab models and may ultimately be useful in treating Alzheimer’s disease (AD).

This new findings on the compound, IRL-1620, were presented at the 2013 American Association of Pharmaceutical Scientists (AAPS) annual meeting and exposition, the world’s largest pharmaceutical sciences meeting, held in San Antonio (TX, USA), November 10-14, 2013.

Anil Gulati, MD, PhD, FCP, and Seema Briyal, PhD, along with their colleagues from Midwestern University (Downers Grove, IL, USA), administered Amyloid beta (Aβ), a key component of specific deposits located in AD patients’ brains, to normal and diabetic rats on days 1, 7, and 14. The lab rat’s spatial learning and memory were assessed in a Morris water maze. The pool was separated into four equal quadrants, and an escape platform was hidden below the surface at a fixed location in one of the quadrants.

The rats had to locate the platform within 60 seconds. The average time it took on day 4 for Aβ-treated rats to locate the platform was 55.05 seconds, though most of this group was not able to find it in the allotted time. Aβ rats treated with IRL-1620 were able to find the platform in 26.53 seconds, nearly 50% the time. After five days, Aβ rats treated with IRL-1620 showed a 60% improvement in learning and memory.

“Our research is based on the idea of using the endothelin [ET] system in the treatment of AD,” said Dr. Gulati. “The ET system is traditionally known to play a role in the regulation of blood flow. This is important in the potential treatment of AD since disturbances in blood flow could damage the brain’s ability to clear damaging particles, leading to a buildup of toxic substances and cognitive impairment.”

The next stage of the research is to additionally study the endothelin receptor type B’s mechanisms of neuroprotection and to look into possible resulting tissue changes following AD.

The US Food and Drug Administration (FDA) has approved five medications to treat the symptoms of AD. Current agents help disguise the symptoms but do not treat the underlying disease. A breakthrough AD treatment would target the underlying disease and stop or delay the cell damage that ultimately leads to the aggravation of symptoms.

Related Links:

Midwestern University

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.